RMC No. 5-2022 republishes the FDA-endorsed updates to VAT-exempt products, affecting businesses handling medicines for kidney diseases. Immediate compliance is required.
Businesses handling medicines for kidney diseases and related health products must update their VAT exemption practices immediately. RMC No. 5-2022 republishes the Food and Drug Administration’s letter endorsing updates to the list of VAT-exempt products under Sections 109(1)(AA) and 109(1)(BB)(ii) of the Tax Code, as amended by R.A. Nos. 10963 and 11534. This impacts pharmacies, hospitals, and distributors who must ensure correct VAT treatment on these items.
What Changed
The circular publishes the FDA’s endorsement and includes the